Charles Schwab Investment Management Inc. Acquires 73,623 Shares of Enovis Co. (NYSE:ENOV)

Charles Schwab Investment Management Inc. grew its holdings in shares of Enovis Co. (NYSE:ENOV) by 14.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 600,819 shares of the company’s stock after buying an additional 73,623 shares during the quarter. Charles Schwab Investment Management Inc. owned 1.08% of Enovis worth $25,865,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ridgewood Investments LLC bought a new position in Enovis in the second quarter worth approximately $44,000. DekaBank Deutsche Girozentrale bought a new position in Enovis in the third quarter worth approximately $55,000. Innealta Capital LLC bought a new position in Enovis in the second quarter worth approximately $65,000. Benjamin F. Edwards & Company Inc. grew its stake in Enovis by 28.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after purchasing an additional 371 shares in the last quarter. Finally, Heritage Family Offices LLP bought a new position in Enovis in the third quarter worth approximately $206,000. Institutional investors own 98.45% of the company’s stock.

Enovis Stock Performance

Shares of ENOV opened at $48.62 on Thursday. Enovis Co. has a 12 month low of $38.27 and a 12 month high of $65.03. The stock has a fifty day moving average price of $43.53 and a 200-day moving average price of $44.78. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The firm has a market cap of $2.72 billion, a PE ratio of -22.20 and a beta of 1.94.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. During the same quarter in the prior year, the business posted $0.56 EPS. The business’s revenue for the quarter was up 21.0% compared to the same quarter last year. Equities research analysts predict that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on ENOV. Needham & Company LLC reissued a “buy” rating and issued a $65.00 price objective on shares of Enovis in a research note on Thursday, November 7th. Evercore ISI lowered their target price on Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a report on Tuesday, October 1st. JMP Securities initiated coverage on Enovis in a report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 target price for the company. Finally, JPMorgan Chase & Co. lowered their target price on Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Enovis presently has an average rating of “Moderate Buy” and an average price target of $67.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.